  Gutz Technologies builds multi-omics AI for drug repositioning and experimental design.

  Most therapies don't fail because the molecule doesn't work — they fail because it only works in a subpopulation that trials never isolated. We model patient biology across multiple molecular layers — gut microbiome, metabolomics, genomics, and transcriptomics — to resolve heterogeneous patient populations into well-defined biological subtypes.

  That resolution powers two things our partners can act on:

  → Drug repositioning — surfacing existing, already-de-risked compounds likely to work for specific biological subtypes, with the evidence behind them.

  → Experimental design — stratifying trial cohorts and selecting biomarker panels that maximize signal and statistical power before a study is run.

  Our edge is what single-test methods can't match: integration across multiple biological layers (exponentially more accurate than any one assay), models that learn how biology changes over time, and a focus on
  causes rather than correlations. The methodology is validated in Nature Neuroscience, Nature Methods, and Nature Communications, and trained on over 1 million curated biological samples.

  We're the core computational modeling team for Wellcome LEAP's FORM program, working alongside 20+ leading research institutions. Our initial focus is autism spectrum disorder, with the platform applicable across
  oncology, autoimmune, and neurological disease.

  Partnering with pharma and research teams → gutztechnologies.com

Gutz Technologies

Org chart

Teams

Offices

Gutz Technologies

Org chart

Teams

Offices

Related companies